

PRODUCT INFORMATION



Soluble BCMA/CD269 (human, recombinant)


Item No. 43757

Overview and Properties

Synonyms:	BCMP, B Cell Maturation Protein, CD269, TNFRSF17, TNF Receptor Superfamily Member 17
Source:	Active recombinant C-terminal human IgG1 Fc-tagged soluble BCMA expressed in HEK293 cells
Amino Acids:	1-54
Uniprot No.:	Q02223
Molecular Weight:	32.6 kDa
Storage:	-80°C (as supplied)
Stability:	1 year
Purity:	≥95% estimated by SDS-PAGE
Supplied in:	Lyophilized from sterile PBS, pH 7.4
Endotoxin Testing:	<1.0 EU/μg, determined by the LAL endotoxin assay
Bioactivity:	See figures for details


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images




Lane 1: MW Markers
Lane 2: Soluble BCMA/CD269

SDS-PAGE Analysis of Soluble BCMA/CD269. This protein has a calculated molecular weight of 32.6 kDa. It has an apparent molecular weight of approximately 40 kDa by SDS-PAGE under reducing conditions.



Measured by its binding ability in a binding assay. Immobilized recombinant human BCMA (CD269) at 2 μg/ml (100 μl/well) can bind biotinylated anti-BCMA antibody, human IgG1. The EC₅₀ value is 0.5-2 ng/ml.



WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/09/2025

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

B cell maturation antigen (BCMA), also known as CD269, is a member of the TNF receptor superfamily.¹ It is composed of an extracellular domain, a transmembrane region, and a cytoplasmic domain.^{1,2} BCMA is found in the cell membrane of late memory B cells and recognizes TNF superfamily member 13B (TNFSF13B), also known as B cell activating factor (BAFF), and a proliferation-inducing ligand (APRIL), which both promote B cell survival and differentiation into short- or long-lived plasma cells, antibody production, and immunoglobulin class switching.^{1,3} The extracellular domain of BCMA can be cleaved by γ -secretase to release soluble BCMA (sBCMA), which can bind APRIL and prevent APRIL-induced signaling in B cells.² Increased sBCMA levels are associated with lower progression-free- and overall survival in patients with multiple myeloma.⁴ Cayman's Soluble BCMA/CD269 (human, recombinant) protein can be used for protein binding assays using biolayer interferometry. This protein is a disulfide-linked homodimer. The reduced monomer, composed of BCMA (amino acids 1-54) fused to human IgG1 Fc at its C-terminus, consists of 292 amino acids and has a calculated molecular weight of 32.6 kDa. As a result of glycosylation, the monomer migrates at approximately 41.3 kDa by SDS-PAGE under reducing conditions.

References

1. Cho, S.-F., Anderson, K.C., and Tai, Y.-T. Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy. *Front. Immunol.* **9**, 1821 (2018).
2. Laurent, S.A., Hoffmann, F.S., Kuhn, P.-H., *et al.* γ -Secretase directly sheds the survival receptor BCMA from plasma cells. *Nat. Commun.* **6**, 7333 (2015).
3. Stohl, W. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. *Endocr. Metab. Immune Disord. Drug Targets* **6(4)**, 351-358 (2006).
4. Ghermezi, M., Li, M., Vardanyan, S., *et al.* Serum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients. *Haematologica* **102(4)**, 785-795 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM